Amyotrophic Lateral Sclerosis: all 1,000 studies

Page 10 of 10. Open to participants first (284), then studies with results posted, then the rest; newest registration first within each.

• Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT01016522Phase 3
• Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT00982150Phase 2
• Effects of Nocturnal Non-invasive Ventilation in Patients With Amyotrophic Lateral SclerosisCompletedNCT00958048Not applicable
• Assessment of Postural Orientation and Equilibrium In Early Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00956501
• Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral AclerosisCompletedNCT00956488Phase 1/2
• Effect of Lithium Carbonate in Patients With Amyotrophic Lateral SclerosisCompletedNCT00925847Phase 2
• Combination Therapy in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00919555Phase 1/2
• Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS)Status unknownNCT00886977Phase 2
• Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00879593Not applicable
• Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00876772Phase 2/3
• First Time in Human Study of GSK1223249 in Amyotrophic Lateral SclerosisCompletedNCT00875446Phase 1
• Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral SclerosisCompletedNCT00855400Phase 1/2
• Neuromuscular Transmission in Amyotrophic Lateral SclerosisCompletedNCT00847847Not applicable
• Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)WithdrawnNCT00846560
• Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular DisordersTerminatedNCT00839033Phase 3
• Muscle Ultrasound: A New Tool for Measuring Progression in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00838617
• Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral SclerosisCompletedNCT00833820Phase 2/3
• Genetics of Familial and Sporadic ALSCompletedNCT00821132
• Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00812851Not applicable
• Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00809224
• A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral SclerosisCompletedNCT00800501Phase 1/2
• Cistanche Total Glycosides for Amyotrophic Lateral Sclerosis: A Randomized Control Trial (RCT) Study Assessing Clinical ResponseStatus unknownNCT00753571Phase 2
• Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00748501Phase 2
• Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient PopulationCompletedNCT00718497
• EEG-Based Brain-Computer Interface Project for Individuals With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00718458
• Pennsylvania Consortium: Clinical DatabaseTerminatedNCT00718445
• Compassionate Use of Ceftriaxone in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00718393
• Satisfaction Survey for Amyotrophic Lateral Sclerosis (ALS) Patients Comparing Rooms With and Without Assistive TechnologyTerminatedNCT00718107
• Assessment of the Cyberlink Control System for Use by the Amyotrophic Lateral Sclerosis (ALS) PatientTerminatedNCT00718016
• Noninvasive Examination of the Work of Breathing in Patients With Amyotrophic Lateral Sclerosis (ALS).TerminatedNCT00718003
• Amyotrophic Lateral Sclerosis (ALS) Tissue Donation ProgramCompletedNCT00716131
• Non-Invasive Measurement of Gastrointestinal (GI) Motility in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00714805
• Cerebrospinal Fluid RepositoryCompletedNCT00714636
• Quantitative Measurement of Nutritional Substrate Utilization in Patients With Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT00714220
• Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral SclerosisCompletedNCT00706147Phase 2/3
• Talampanel for Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00696332Phase 2
• A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00694941Phase 2
• Study of Pioglitazone in Patients With Amyotrophic Lateral SclerosisTerminatedNCT00690118Phase 2
• Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00677768
• Far Infrared Irradiation for Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS)Status unknownNCT00673140Phase 1
• Growth Hormone in Amyotrophic Lateral SclerosisCompletedNCT00635960Phase 2
• Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS)CompletedNCT00613899Phase 4
• Validation of a New Device to Measure Neuromuscular Disease ProgressionCompletedNCT00606918
• R(+)PPX High Dose Treatment of ALSCompletedNCT00600873Phase 1/2
• Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/DayTemporarily not availableNCT00596115
• Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00580593Phase 1
• Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral SclerosisStatus unknownNCT00563537Phase 1
• A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALSWithdrawnNCT00561366Phase 2
• Non-Invasive Ventilation in Amyotrophic Lateral SclerosisStatus unknownNCT00560287Phase 4
• CARE Canadian ALS Riluzole EvaluationCompletedNCT00542412Phase 4
• Efficacy of Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00537641
• A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00445172Phase 2/3
• A Study in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00444613Phase 2/3
• Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)Status unknownNCT00420719Not applicable
• The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00409721Phase 2
• Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00403104Phase 2
• G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical ResponseCompletedNCT00397423Phase 2
• Noninvasive Ventilation in ALS Patients With Mild Respiratory InvolvementCompletedNCT00386464Phase 2/3
• Confirmation of Self-Reported Incident ALS Cases in the AARP-Diet and Health (AARP-DH) CohortCompletedNCT00377351
• Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALSCompletedNCT00372879Phase 3
• Collection of Blood Samples for DNA in Motor Neuron DiseaseCompletedNCT00362362
• Combination Therapy Selection Trial in Amyotrophic Lateral SclerosisCompletedNCT00355576Phase 2
• Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)CompletedNCT00353665Phase 2/3
• Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral SclerosisCompletedNCT00339976
• Effects of Gastrostomy on Amyotrophic Lateral SclerosisCompletedNCT00337402
• Brain Function in Primary Lateral Sclerosis and Amyotrophic Lateral SclerosisCompletedNCT00334516
• Mitochondrial Functions and Oxidative Stress in ALS PatientsStatus unknownNCT00331812
• Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron DiseaseCompletedNCT00324454Phase 2
• Amyotrophic Lateral Sclerosis Web Based Patient Care Database: ALSConnection.OrgCompletedNCT00302198
• Influence of G-CSF and EPO on Associative Learning and Motor SkillsCompletedNCT00298597Phase 2
• A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALSCompletedNCT00244244Phase 2
• Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT00231140Phase 2
• A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)CompletedNCT00230074Phase 2
• Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]CompletedNCT00214110Phase 2
• A Study of the Expression of Nogo and Reticulon Genes in Skeletal Muscle of Patients With Amyotrophic Lateral SclerosisTerminatedNCT00213824
• Study of the Effects Strengthening Exercises in Individuals With ALSCompletedNCT00204464Phase 2
• The Effect of Intensive Controlled Exercise in the Early Stages of Amyotrophic Lateral SclerosisTerminatedNCT00160004Phase 1/2
• Amyotrophic Lateral Sclerosis and Frontotemporal DementiaTerminatedNCT00159198
• Phase II Study Using Thalidomide for the Treatment of ALSCompletedNCT00140452Phase 2
• R(+) Pramipexole in Early Amyotrophic Lateral SclerosisCompletedNCT00140218Phase 1/2
• Trial of Sodium Valproate in Amyotrophic Lateral SclerosisCompletedNCT00136110Phase 3
• Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00125203Phase 2/3
• Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis)CompletedNCT00107770Phase 1/2
• National Registry of Veterans With Amyotrophic Lateral Sclerosis and DNA BankCompletedNCT00076154
• Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00072709Phase 2
• Brain Function in Primary Lateral SclerosisCompletedNCT00071435
• Creatine for the Treatment of Amyotrophic Lateral SclerosisCompletedNCT00070993Phase 2
• Study of Creatine Monohydrate in Patients With Amyotrophic Lateral SclerosisStatus unknownNCT00069186Phase 3
• Minocycline to Treat Amyotrophic Lateral SclerosisCompletedNCT00047723Phase 3
• A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral SclerosisCompletedNCT00036413Phase 2
• Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral SclerosisCompletedNCT00023075
• Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALSCompletedNCT00021697Phase 3
• Exogenous Toxicants and Genetic Susceptibility in ALSCompletedNCT00011154
• Amyotrophic Lateral Sclerosis (ALS) Gulf War StudyCompletedNCT00007722
• Clinical Trial of Creatine in Amyotrophic Lateral SclerosisCompletedNCT00005766Phase 2
• Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]CompletedNCT00005674Phase 2
• Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron DiseaseCompletedNCT00004771Phase 2
• Determinants of Disease Severity in Amyotrophic Lateral SclerosisStatus unknownNCT00004457
• Magnetic Stimulation of the Human Nervous SystemCompletedNCT00001780
• Ultrasound and Videofluoroscopy for Diagnosing Swallowing DisordersCompletedNCT00001220

← Amyotrophic Lateral Sclerosis overview